Trials / Completed
CompletedNCT01408472
NT-501 CNTF Implant for Glaucoma: Safety, Neuroprotection and Neuroenhancement
CNTF Cell Implants For Glaucoma: A Phase I Study
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Jeffrey L Goldberg · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Ciliary Neurotrophic Factor (CNTF) has been demonstrated in multiple pre-clinical models to enhance survival and regeneration of retinal ganglion cells, the retinal neurons injured in diseases like glaucoma. We hypothesize that CNTF delivery to the human eye will provide neuroprotection (prevent loss of vision) and neuroenhancement (improve vision indices) in glaucoma. Patients in the trial will receive an NT-501 CNTF implant (made by Neurotech) into one eye, and will be carefully followed to evaluate safety and efficacy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NT-501 CNTF Implant | Single implantation of CNTF-secreting NT-501 device into one eye |
Timeline
- Start date
- 2011-04-01
- Primary completion
- 2013-12-01
- Completion
- 2014-10-01
- First posted
- 2011-08-03
- Last updated
- 2016-08-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01408472. Inclusion in this directory is not an endorsement.